幽门螺杆菌
医学
抗生素耐药性
抗菌剂
内科学
抗药性
胃炎
药物治疗
人口
消化性
胃肠病学
消化性溃疡
重症监护医学
抗生素
微生物学
环境卫生
生物
作者
Samantha Flores-Treviño,Soraya Mendoza-Olazarán,Paola Bocanegra-Ibarias,Héctor Jesús Maldonado-Garza,Elvira Garza-González
标识
DOI:10.1080/17474124.2018.1496017
摘要
Helicobacter pylori is a Gram-negative bacterium that causes chronic gastritis, dyspepsia, peptic ulcers, and gastric cancer. Over half the world's population is infected with H. pylori, with higher prevalence in developing countries. Areas covered: In this review, current guidelines on H. pylori therapy, such as the Toronto consensus statement, the Maastricht V/Florence consensus report, and the American College of Gastroenterology guidelines, are compared. Also, we analyzed reports of antimicrobial resistance of H. pylori published in PubMed in the last years to determine current antimicrobial resistance worldwide. Expert commentary: Although H. pylori antimicrobial resistance varies by geographic area, its prevalence has been increasing over time, causing therapy failures and low eradication rates. To best optimize the management of H. pylori infection, H. pylori therapy should be based on patterns of local and individual antimicrobial resistance, if possible.
科研通智能强力驱动
Strongly Powered by AbleSci AI